September/October 2023

Featured Article

Clinical Pathways GPS

Retired Physicians as Patient Navigators in Oncology: Guiding Patients Through the Complex Health Care System

09/19/2023

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Richard G. Stefanacci, DO, discusses the important role retired physicians play as patient navigators, with a focus on oncology care.

Richard G. Stefanacci, DO,...

09/19/2023

Journal of Clinical Pathways

Editor's Page

The Roles of Comprehensive Genomic Profiling, Next-Generation Sequencing, and AI in the Oncology Treatment Landscape

09/19/2023

Winston Wong, PharmD, Editor-in-Chief

Editor-in-Chief Winston Wong, PharmD, provides insights on this issue’s content, highlighting the latest scientific developments in genetic testing for oncology biomarkers into clinical care.

Editor-in-Chief Winston Wong,...

09/19/2023

Journal of Clinical Pathways

Research Reports

Off-Label Use of Precision Oncology Therapeutics in Advanced Solid Cancers Following Identification of Associated Variants via Multicancer Next-Generation Sequencing Panel: A Real-World Evidence Pilot Study

09/19/2023

Julie Wiedower, PhDc

Nicole Zhang, MPH

Rebecca Nagy, MS

Kathryn Lang, MD

Jayati Saha, PhD, MPH

Julie Wiedower, PhDc, and colleagues analyze the frequency of real-world off-label therapy utilization post–comprehensive genomic profiling via liquid biopsy in precision oncology.

Julie Wiedower, PhDc, and...

09/19/2023

Journal of Clinical Pathways

Department

Clinical Pathways Forum

Precision Medicine Testing in Oncology: Benefits of and Barriers to Adoption

09/19/2023

Mishellene McKinney, MHA, RN, OCN—Column Editor

For the May 2023 Clinical Pathways Forum, Suzzette Arnal, PhD, addressed the Forum about precision medicine and how The US Oncology Network has worked to increase precision medicine testing across their organization.

For the May 2023 Clinical...

09/19/2023

Journal of Clinical Pathways

Feature

Review

NGS Testing in Non–Small Cell Lung Cancer

09/19/2023

Winston Wong, PharmD

Gordon Kuntz

Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...

Winston Wong, PharmD, and Gordon...

09/19/2023

Journal of Clinical Pathways

OCPC: IN SESSION

Artificial Intelligence in Oncology: The Wins, The Challenges, and How We Can Deliver on Personalized Cancer Care

09/19/2023

Matthew Biancalana, PhD

Tushar Pandey, MBA

Mathew Biancalana, PhD, and Tushar Pandey, MBA, discuss how artificial intelligence can enhance the field of precision medicine and help unburden physicians from laborious and repetitive tasks in diagnostic analyses.

Mathew Biancalana, PhD, and...

09/19/2023

Journal of Clinical Pathways

Column

Trending From ACCC

Key Findings from ACCC’s Digital Tools Survey

09/19/2023

Association of Community Cancer Centers

This column describes the findings from the 2022 Association of Community Cancer Centers (ACCC) patient survey to identify challenges and benefits associated with wearable devices and other digital tools.

This column describes the...

09/19/2023

Journal of Clinical Pathways

COA Viewpoint

Is the EOM DOA?

09/19/2023

Nicolas Ferreyros, Managing Director, Community Oncology Alliance

Nicolas Ferreyros discusses the impact, or the lack of impact, the launch of the Enhancing Oncology Model has had on practices.

Nicolas Ferreyros discusses the...

09/19/2023

Journal of Clinical Pathways

Transformative Employer Trends

Navigating Personalized Medicine: Challenges and Opportunities for Employer Plans

09/19/2023

Ira Klein, MD, MBA, FACP

F. Randy Vogenberg, PhD, FASHP

This installment of the Transformative Employer Trends column further explores ways to address access to gene and cell therapies that are transforming management of benefits by employer plans.

This installment of the...

09/19/2023

Journal of Clinical Pathways

MAI Mindset

Clinical Pathways Impact on Treatment Selection

09/19/2023

Lee Blansett, MBA

In this first entry of our new MAI Mindset column, Lee Blansett, MBA, provides an overview of how in addition to providing benefits, clinical pathways can also present challenges and potential risks for manufacturers.

In this first entry of our new...

09/19/2023

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

September/October 2023

Featured Article

Department

Feature

Column

Current Issue

Special Reports

Subscribe

September 2023 Volume 9 Issue 5

Specialties

Events

Year Round Education

HMP Global Products